Last updated: Jun 1, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT06064097 | 2 | A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) | PD-1 -- immune checkpoint inhibitor (monoclonal antibody) |
| NCT07590024 | 3 | RAIRI-Guided Adjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma | PD-1 -- immune checkpoint inhibitor |
| NCT05910827 | 1, 2 | A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers | HER3 + EGFR -- monoclonal antibodies targeting HER3 and EGFR |
| NCT07325539 | 2 | LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC | PD-1 -- immune checkpoint inhibitor (monoclonal antibody) |
| NCT07236190 | 2 | Biomarker-based Trial of NPC-1 for Alzheimer's Pathology | Unknown mechanism |
| Sponsor | Recruiting trials |
|---|---|
| Sun Yat-sen University | 77 |
| Fujian Cancer Hospital | 9 |
| Jiangxi Provincial Cancer Hospital | 8 |
| Fudan University | 8 |
| Zhejiang Cancer Hospital | 6 |
Countries/regions with the most active trial sites for nasopharyngeal carcinoma. A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Apr 2026 | NCT07247201 | Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients | Natural Killer cells -- adoptive cell therapy |
| Mar 31, 2026 | NCT07320963 | Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. | HDAC + PD-1 + VEGFR -- HDAC inhibitor + immune checkpoint inhibitor + multi-kinase inhibitor |
| Jul 9, 2025 | NCT06802835 | EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma | EGFR + PD-1 -- EGFR inhibition and immune checkpoint blockade (monoclonal antibodies) |
You've seen the nasopharyngeal carcinoma landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.